Emile E. Voest
0000-0001-8249-9586
Publication & Citation Trends
Publications
0 total
BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.
Cited by 0
Semantic Scholar
Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer
Cited by 1
Semantic Scholar
Subclonal immune evasion in non-small cell lung cancer.
Cited by 12
Semantic Scholar
Procedure for pooling clinical outcome data from DRUP-like clinical trials using the OMOP model.
Cited by 0
Semantic Scholar
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy
Cited by 0
Semantic Scholar
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol
Cited by 1
Semantic Scholar
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(172)
Cancer Immunotherapy and Biomarkers
(158)
Colorectal Cancer Treatments and Studies
(110)
Lung Cancer Treatments and Mutations
(80)
Cancer Cells and Metastasis
(73)
Affiliations
AstraZeneca (United Kingdom)
Boston Children's Hospital
OncoMed (United States)
American Society of Clinical Oncology
Beth Israel Deaconess Medical Center